Open-label, active-control, phase 2/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma.

被引：0
|
作者：
Cobb, Patrick Wayne
Zhou, Heng
Nahar, Akash
Marinello, Patricia
机构：
[1] St Vincent Healthcare Canc Ctr Montana, Billings, MT USA
[2] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7592
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Open-label phase 2 study of bispecific T-cell engager (BiTE®) antibody blinatumomab in patients (pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Viardot, A.
    Goebeler, M.
    Pfreundschuh, M.
    Adrian, N.
    Libicher, M.
    Hess, G.
    Zettl, F.
    Neumann, S.
    Degenhard, E.
    Stieglmaier, J.
    Zhang, A.
    Nagorsen, D.
    Bargou, R. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 33 - 33
  • [42] Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Triguero, Ana
    Banerjee, Lalita
    Mcmillan, Andrew
    Seymour, Erlene
    Hirata, Jamie
    de Guzman, Jayson
    Sharma, Sunil
    Jin, Hyun Yong
    Musick, Lisa
    Diefenbach, Catherine
    LANCET HAEMATOLOGY, 2024, 11 (02): : e136 - e146
  • [43] Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
    Bartlett, Nancy L.
    Assouline, Sarit
    Giri, Pratyush
    Schuster, Stephen J.
    Cheah, Chan Y.
    Matasar, Matthew
    Gregory, Gareth P.
    Yoon, Dok Hyun
    Shadman, Mazyar
    Fay, Keith
    Yoon, Sung-Soo
    Panizo, Carlos
    Flinn, Ian
    Johnston, Anna
    Bosch, Francesc
    Sehn, Laurie H.
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Budde, Lihua E.
    BLOOD ADVANCES, 2023, 7 (17) : 4926 - 4935
  • [44] Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Mehta, Amitkumar
    Salles, Gilles
    Haioun, Corinne
    Munoz, Javier
    Chen, Andy I.
    Kolibaba, Kathryn
    Lu, Dan
    Yan, Mark
    Penuel, Elicia
    Hirata, Jamie
    Lee, Calvin
    Sharman, Jeff P.
    LANCET ONCOLOGY, 2019, 20 (07): : 998 - 1010
  • [45] Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
    Abramson, Jeremy S.
    Ku, Matthew
    Hertzberg, Mark
    Huang, Hui-Qiang
    Fox, Christopher P.
    Zhang, Huilai
    Yoon, Dok Hyun
    Kim, Won-Seog
    Abdulhaq, Haifaa
    Townsend, William
    Herbaux, Charles
    Zaucha, Jan M.
    Zhang, Qing-Yuan
    Chang, Hung
    Liu, Yanyan
    Cheah, Chan Yoon
    Ghesquieres, Herve
    Simko, Stephen
    Orellana-Noia, Victor
    Ta, Richard
    Relf, James
    Dixon, Mark
    Kallemeijn, Martine
    Mulvihill, Estefania
    Huang, Huang
    Lundberg, Linda
    Gregory, Gareth P.
    LANCET, 2024, 404 (10466): : 1940 - 1954
  • [46] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Ren, Liangliang
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Yan, Jiaqin
    Kong, Fei
    Zhang, Mingzhi
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
  • [47] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Liangliang Ren
    Ling Li
    Lei Zhang
    Xin Li
    Xiaorui Fu
    Xinhua Wang
    Jingjing Wu
    Zhenchang Sun
    Xiaoyan Feng
    Yu Chang
    Zhiyuan Zhou
    Feifei Nan
    Jiaqin Yan
    Fei Kong
    Mingzhi Zhang
    Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
  • [48] Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study
    Kim, Jeong A.
    Hahn, Uwe
    Kim, Won-Seog
    Fleury, Isabelle
    Laribi, Kamel
    Burgues, Juan Miguel Bergua
    Bouabdallah, Krimo
    Forward, Nick
    Bijou, Fontanet
    MacDonald, David
    Portell, Craig Anthony
    Ghesquieres, Herve
    Nowakowski, Grzegorz S.
    Yasenchak, Christopher A.
    Rustia, Evelyn
    Fanale, Michelle
    Jie, Fei
    Bartlett, Nancy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA7005 - LBA7005
  • [49] Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma
    Ward, Jeffrey P.
    Berrien-Elliott, Melissa M.
    Gomez, Felicia
    Luo, Jingqin
    Becker-Hapak, Michelle
    Cashen, Amanda F.
    Wagner-Johnston, Nina D.
    Maddocks, Kami
    Mosior, Matthew
    Foster, Mark
    Krysiak, Kilannin
    Schmidt, Alina
    Skidmore, Zachary L.
    Desai, Sweta
    Watkins, Marcus P.
    Fischer, Anne
    Griffith, Malachi
    Griffith, Obi L.
    Fehniger, Todd A.
    Bartlett, Nancy L.
    BLOOD, 2022, 139 (13) : 1999 - 2010
  • [50] A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007
    David, Lavie
    Muhit, Ozcan
    Ewa, Paszkiewicz-Kozik
    Eva, Gonzalez Barca
    Min, Kim Tae
    Benedetta, Puccini
    Siruo, Wang
    Rushdia, Yusuf
    Patricia, Marinello
    Seog, Kim Won
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S31 - S32
12345